PET scan study for breast cancer with hormone receptors
Part of Cancer clinical trials.
This study tests a special PET scan called 68Ga-DOTATOC to see if it can find certain breast cancer cells in the body. It may help doctors better understand your cancer, especially if it has spread to the liver or bones.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have breast cancer that has spread to other parts of the body (metastatic).
- You have already had at least one type of treatment for metastatic breast cancer.
- Your original breast cancer was hormone receptor positive (ER+) and HER2 negative.
- You have at least 10 spots of cancer found on a standard PET scan.
- You are willing to have a second PET scan within 21 days of your first one.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
This trial uses a special PET scan to see how well it can find and track different types of cancer. It may help doctors better understand your cancer.
This trial uses a special PET/CT scan to find breast cancer cells that have a certain marker (CD73). It may help doctors see the cancer more clearly before you start other treatments.
This trial uses a special PET scan with a new tracer called 68Ga-DOTA-BLP to spot cancer and its spread in the body. It aims to see if this scan can find tumors in lymph nodes or other areas without needing more painful biopsies.
This study tests whether a specific special scan (68-Gallium DOTATATE PET/CT) can help doctors better see where thyroid cancer has spread. It focuses on certain types of thyroid cancer and compares how well the scan images metastases.
This study tests an imaging scan using a special tracer (68Ga-HA-DOTATATE) to look for tumors that have somatostatin receptors. It may help doctors better locate suspected tumor sites so treatment planning can be more accurate.
Hear when a new Breast Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.